Luye Pharma Group Ltd.
Símbolo: 2186.HK
HKSE
3.02
HKDPrecio de mercado actual
19.0836
Ratio PER
1.7261
Ratio PEG
11.36B
Capitalización MRK
- 0.00%
Rendimiento DIV
Luye Pharma Group Ltd. (2186-HK) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 30442.4 | 8522.3 | 5544.3 | 5510.3 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 8899.94 | 2867.5 | 3220.5 | 3072.1 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 9083.1 | 2354.9 | 1783.7 | 1765.1 | ||||||||||||||||||||
balance-sheet.row.inventory | 3262.94 | 827.9 | 772.9 | 746.3 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 14658.34 | 3009.9 | 4658.7 | 5059.1 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 47624.65 | 10703.3 | 10785.8 | 10396.7 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 19926.44 | 5127.2 | 4909.1 | 4594.5 | ||||||||||||||||||||
balance-sheet.row.goodwill | 4170.88 | 1041.9 | 1003.4 | 985.4 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 25053.85 | 6317.9 | 5984.7 | 5441.8 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 29224.74 | 7359.8 | 6988.1 | 6427.2 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 1699.95 | 1968.4 | -2106.4 | -2489.9 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 291.01 | 144.6 | 113.9 | 133.1 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 4815.04 | 187.4 | 3559.1 | 3520.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 55957.17 | 14787.4 | 13463.8 | 12185.4 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.account-payables | 2864.67 | 767.2 | 559.9 | 570.9 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 25899.19 | 5195.8 | 6839.8 | 5263.2 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 565.73 | 294.9 | 256.3 | 205.1 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 10671.39 | 3228.2 | 2264.7 | 4227.6 | ||||||||||||||||||||
Deferred Revenue Non Current | 264.72 | 103.6 | 175 | 209.4 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 94.99 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 10345.67 | 2193.4 | 2087.5 | 1496.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 13045.19 | 3824.4 | 3720.7 | 6138 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 223.17 | 70.6 | 38.5 | 42 | ||||||||||||||||||||
balance-sheet.row.total-liab | 52136.22 | 11962.2 | 13207.9 | 13468.2 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 1944.43 | 486.1 | 457 | 455.8 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 14005.23 | 0 | 6667.3 | 6061.8 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 16081.52 | 7885.8 | 254.5 | 534 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 15700.8 | 4159.3 | 2797.3 | 1436.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 47731.99 | 12531.2 | 10176 | 8488.1 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 3713.61 | 997.3 | 865.8 | 625.8 | ||||||||||||||||||||
balance-sheet.row.total-equity | 51445.6 | 13528.5 | 11041.7 | 9113.9 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 103581.81 | - | - | - | ||||||||||||||||||||
Total Investments | 7732.43 | 1968.4 | 1114.1 | 582.2 | ||||||||||||||||||||
balance-sheet.row.total-debt | 36570.58 | 8423.9 | 9104.5 | 9490.8 | ||||||||||||||||||||
balance-sheet.row.net-debt | 18731.27 | 2769.1 | 6780.8 | 7052.5 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 532.61 | 669.8 | -74.6 | 942.2 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 331.43 | 671.3 | 582 | 510.9 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | -914.59 | 0 | -311.9 | -505.9 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 20.64 | 25.4 | 50 | 50.9 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 186.15 | 319.8 | -418.1 | -300.3 | |||||||||||||||||||
cash-flows.row.account-receivables | -403.05 | -18.8 | -211.8 | 145 | |||||||||||||||||||
cash-flows.row.inventory | -30.67 | -26.6 | -134 | 4.9 | |||||||||||||||||||
cash-flows.row.account-payables | 118.98 | 18.8 | 211.8 | -145 | |||||||||||||||||||
cash-flows.row.other-working-capital | 619.86 | 346.4 | -284 | -305.2 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -381.1 | -32.5 | 355 | 335.7 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 689.73 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -544.22 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0.11 | 0 | -808.5 | -450.8 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -218.72 | -3485.9 | -3975.7 | -2859.2 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 627.68 | 2899.5 | 1919 | 4153.8 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -78.02 | 91.8 | 970.7 | 814.2 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -78.02 | -1658.3 | -3436 | 138.2 | |||||||||||||||||||
cash-flows.row.debt-repayment | -561.84 | -8301.9 | -7536.7 | -5896.7 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 1043.83 | 189.2 | 1044.5 | 7326.7 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -78 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | -175.5 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 1522.95 | 8166.9 | 8371.1 | -922.6 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 1522.95 | 54.1 | 1878.9 | 254 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 14.37 | -164.1 | -52.4 | 112.4 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 3254.94 | -114.5 | -1427.1 | 1538 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 5899.82 | 2323.7 | 2438.3 | 3865.4 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2644.89 | 2438.3 | 3865.4 | 2327.3 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 689.73 | 1653.8 | 182.4 | 1033.4 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -544.22 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 145.51 | 490.1 | -1359.2 | -486.4 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 6143.08 | 6143.1 | 5981.7 | 5200.2 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1938.9 | 1938.9 | 1841.1 | 1803.5 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 4204.18 | 4204.2 | 4140.5 | 3396.7 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 586.16 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 643.97 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 2056.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.3 | -73.3 | 155.2 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 3038.59 | 3175.4 | 3186.6 | 3113.9 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4977.49 | 5114.4 | 5027.8 | 4917.4 | ||||||||||||||||||||
income-statement-row.row.interest-income | 465.49 | 117.1 | 88.7 | 102 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 347.02 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 2056.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -187.34 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.3 | -73.3 | 155.2 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -187.34 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 347.02 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 634.89 | 701.9 | 671.3 | 582 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 1522.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 887.44 | 887.4 | 1215 | 387 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 700.1 | 700.1 | 669.8 | -74.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 161.02 | 161 | 86.5 | 70.2 | ||||||||||||||||||||
income-statement-row.row.net-income | 532.61 | 532.6 | 604.8 | -144.8 |
Preguntas frecuentes
Cuánto es Luye Pharma Group Ltd. (2186.HK) activos totales?
Luye Pharma Group Ltd. (2186.HK) los activos totales son 25490715000.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son 3238970000.000.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.684.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es 0.039.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es 0.087.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son 0.144.
¿Qué es Luye Pharma Group Ltd. (2186.HK) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es 532605000.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 8423947000.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 3175450000.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 5654804000.000.